ATE265220T1 - Kostimulatorische blockade und gemischter chimerismus in allotransplantationen - Google Patents

Kostimulatorische blockade und gemischter chimerismus in allotransplantationen

Info

Publication number
ATE265220T1
ATE265220T1 AT99905798T AT99905798T ATE265220T1 AT E265220 T1 ATE265220 T1 AT E265220T1 AT 99905798 T AT99905798 T AT 99905798T AT 99905798 T AT99905798 T AT 99905798T AT E265220 T1 ATE265220 T1 AT E265220T1
Authority
AT
Austria
Prior art keywords
allotransplants
mixed chimerism
costimulatory blockade
blockade
costimulatory
Prior art date
Application number
AT99905798T
Other languages
English (en)
Inventor
Megan Sykes
Mohamed H Sayegh
Original Assignee
Gen Hospital Corp
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Brigham & Womens Hospital filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE265220T1 publication Critical patent/ATE265220T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99905798T 1998-02-04 1999-02-04 Kostimulatorische blockade und gemischter chimerismus in allotransplantationen ATE265220T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7386498P 1998-02-04 1998-02-04
PCT/US1999/002542 WO1999039727A1 (en) 1998-02-04 1999-02-04 Costimulatory blockade and mixed chimerism in allotransplantation

Publications (1)

Publication Number Publication Date
ATE265220T1 true ATE265220T1 (de) 2004-05-15

Family

ID=22116269

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99905798T ATE265220T1 (de) 1998-02-04 1999-02-04 Kostimulatorische blockade und gemischter chimerismus in allotransplantationen

Country Status (9)

Country Link
US (3) US6514513B1 (de)
EP (2) EP1053006A4 (de)
JP (2) JP2002502823A (de)
AT (1) ATE265220T1 (de)
AU (2) AU748443B2 (de)
CA (2) CA2319448A1 (de)
DE (1) DE69916807T2 (de)
IL (2) IL137614A0 (de)
WO (2) WO1999039727A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0918524A4 (de) * 1996-05-09 2000-11-08 Gen Hospital Corp Gemischter chimerismus und toleranz
WO2000047625A2 (en) * 1999-02-12 2000-08-17 Genetics Institute, Inc. Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
HK1043312B (en) 1999-05-07 2006-07-28 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
WO2001000679A2 (en) * 1999-06-29 2001-01-04 University Of Massachusetts Methods for inducing t cell non-responsiveness to a tissue or organ graft
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
EP1257282A4 (de) * 1999-12-06 2003-05-02 Gen Hospital Corp Pankreatische stammzellen und deren verwendung in transplantation
AU2001247401A1 (en) * 2000-03-14 2001-09-24 Genetics Institute Inc. Therapies that improve graft survival, using antibodies against a b7 antigen
US20020058029A1 (en) * 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
CA2436139A1 (en) * 2001-01-26 2002-08-01 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030031652A1 (en) * 2001-04-16 2003-02-13 Bernhard Hering Systems and methods for inducing mixed chimerism
CA2658221C (en) 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
MXPA03010568A (es) 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
US20050058641A1 (en) * 2002-05-22 2005-03-17 Siemionow Maria Z. Tolerance induction and maintenance in hematopoietic stem cell allografts
WO2003099330A1 (en) * 2002-05-22 2003-12-04 The Cleveland Clinic Foundation Induction and maintenance of tolerance to composite tissue allografts
EP1658096A1 (de) * 2003-08-25 2006-05-24 PanGenetics B.V. Verfahren zur auslösung von immuntoleranz
WO2005021734A2 (en) * 2003-09-02 2005-03-10 University Of Massachussets Generation of hematopoietic chimerism and induction of central tolerance
DK1755674T3 (en) 2004-05-14 2015-02-09 Alexion Pharma Inc PROLONGED SURVIVAL OF A allograft by inhibiting complement activity
US20060045872A1 (en) * 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
US20070113297A1 (en) * 2005-09-13 2007-05-17 Yongguang Yang Methods and compositions for inhibition of immune responses
MX342474B (es) 2005-09-23 2016-09-30 Cellerix Sl Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.
CA2644020C (en) 2006-03-02 2016-05-10 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
WO2011146395A2 (en) * 2010-05-17 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
CA2826453A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
EP3556774B1 (de) 2011-03-11 2024-01-03 Beth Israel Deaconess Medical Center Inc. Anti-cd40-antikörper und verwendungen davon
US9561253B2 (en) 2013-02-26 2017-02-07 The Board Of Trustees Of The Leland Stanford Junior University Combined organ and hematopoietic cells for transplantation tolerance of grafts
EP3033093A1 (de) 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Behandlung von transplantatabstossung durch verabreichung eines komplementinhibitors an ein organ vor der transplantation
CN113699116A (zh) 2014-12-10 2021-11-26 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
KR20250007054A (ko) 2015-09-04 2025-01-13 프리마토프 테라퓨틱스 인크. 인간화 항-cd40 항체 및 그의 용도
US11273179B2 (en) 2018-03-12 2022-03-15 Medeor Therapeutics, Inc. Methods for treating non-cancerous disorders using hematopoietic cells
US10881692B2 (en) 2018-04-05 2021-01-05 Medeor Therapeutics, Inc. Compositions for establishing mixed chimerism and methods of manufacture thereof
US10842821B2 (en) 2018-04-05 2020-11-24 Medeor Therapeutics, Inc. Cellular compositions derived from prior organ donors and methods of manufacture and use thereof
US11435350B2 (en) 2018-09-18 2022-09-06 Medeor Therapeutics, Inc. Methods of analysis of blood from deceased donors
US11813376B2 (en) 2018-09-18 2023-11-14 Medeor Therapeutics, Inc. Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
PT621786E (pt) 1992-01-08 2002-07-31 Gen Hospital Corp Inducao da tolerancia a xenoenxertos
WO1994026289A1 (en) 1992-02-19 1994-11-24 The General Hospital Corporation Allogeneic and xenogeneic transplantation
US5869049A (en) 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
JPH10501815A (ja) * 1994-06-07 1998-02-17 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ 抗原特異的ｔ細胞応答の阻害方法
PT892643E (pt) * 1996-03-20 2002-09-30 Univ Emory Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito
EP0918524A4 (de) 1996-05-09 2000-11-08 Gen Hospital Corp Gemischter chimerismus und toleranz
EP0922111B1 (de) * 1996-07-23 2004-12-01 Tanox Pharma B.V. Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann

Also Published As

Publication number Publication date
DE69916807T2 (de) 2005-01-13
EP1053006A1 (de) 2000-11-22
WO1999039727A1 (en) 1999-08-12
EP1058555A1 (de) 2000-12-13
JP2002502824A (ja) 2002-01-29
AU748443B2 (en) 2002-06-06
IL137361A0 (en) 2001-07-24
US6280957B1 (en) 2001-08-28
JP2002502823A (ja) 2002-01-29
AU746825B2 (en) 2002-05-02
DE69916807D1 (de) 2004-06-03
AU2583999A (en) 1999-08-23
EP1053006A4 (de) 2002-09-25
EP1058555A4 (de) 2001-02-28
CA2319448A1 (en) 1999-08-12
IL137614A0 (en) 2001-07-24
WO1999039726A1 (en) 1999-08-12
US6514513B1 (en) 2003-02-04
EP1058555B1 (de) 2004-04-28
US20020055122A1 (en) 2002-05-09
CA2319764A1 (en) 1999-08-12
AU2588099A (en) 1999-08-23

Similar Documents

Publication Publication Date Title
ATE265220T1 (de) Kostimulatorische blockade und gemischter chimerismus in allotransplantationen
ES2195664T3 (es) Uso de fumaratos de dialquilo.
ES2194106T3 (es) .ompuestos de imidazol
TR200103216T2 (tr) Pirimidinon bileşimleri
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
EP1257282A4 (de) Pankreatische stammzellen und deren verwendung in transplantation
ES2300276T3 (es) P40 de interleuquina-12 de mamifero e interleuquina b30. sus combinaciones. anticuerpos. usos en composiciones farmaceuticas.
DE59709437D1 (de) Neue phenanthridine
DK0733109T3 (da) BMP-12, BMP-13 og seneinducerende præparater dermed
PT935465E (pt) Compostos novos de imidazole substituido
YU28503A (sh) Humanizovana anti-lt-beta-r antitela
DE69630955D1 (de) Immortalisierung bzw. desimmortalisierung von zellen
DK1379671T3 (da) Fremgangsmåder til dyrkning af circovirus
DE69731400D1 (de) Proliferation humaner endokriner pankreaszellen in kultur
FR2749022B1 (fr) Cellules aviaires immortelles
ES2180319T3 (es) Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos.
NO20031860D0 (no) Kahalaolid F
DE60033918D1 (de) Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung
DE69903559D1 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
DK0949221T3 (da) Sammensætning, som er egnet som flydende gödning og som indeholder svovl i form af kaliumtetrathionat
HUP0101393A1 (hu) Redukáló körülményekre érzékeny transzfektáló kompozíciók, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE221388T1 (de) Zusammensetzungen die gemischte transferrine als wirkstoff für induktion von immunotoleranz gegen antigen enthalten
WO1999009167A8 (en) Porcine mhc class i genes and uses thereof
DE60330223D1 (de)
YU180791A (sh) Injekcioni proizvod za sitni pesak i druge porozne materijale

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties